External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
Background. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim. To independently evaluate the predictive performan...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2021/9928065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566256866164736 |
|---|---|
| author | Jakub Gazda Martin Janicko Sylvia Drazilova Ivica Grgurevic Tajana Filipec Kanizaj Tomas Koller Beatrica Bodorovska Maja Mijic Ivana Mikolasevic Ivana Knezevic Stromar Branislav Kucinsky Matej Gazda Peter Jarcuska |
| author_facet | Jakub Gazda Martin Janicko Sylvia Drazilova Ivica Grgurevic Tajana Filipec Kanizaj Tomas Koller Beatrica Bodorovska Maja Mijic Ivana Mikolasevic Ivana Knezevic Stromar Branislav Kucinsky Matej Gazda Peter Jarcuska |
| author_sort | Jakub Gazda |
| collection | DOAJ |
| description | Background. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim. To independently evaluate the predictive performance of the URS model. Methods. We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. Results. One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. Conclusion. Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy. |
| format | Article |
| id | doaj-art-069badd8a34845328fd1dec40843f2b8 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-069badd8a34845328fd1dec40843f2b82025-02-03T01:04:33ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972021-01-01202110.1155/2021/99280659928065External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary CholangitisJakub Gazda0Martin Janicko1Sylvia Drazilova2Ivica Grgurevic3Tajana Filipec Kanizaj4Tomas Koller5Beatrica Bodorovska6Maja Mijic7Ivana Mikolasevic8Ivana Knezevic Stromar9Branislav Kucinsky10Matej Gazda11Peter Jarcuska122nd Department of Internal Medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia2nd Department of Internal Medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia2nd Department of Internal Medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, SlovakiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University of Zagreb School of Medicine, University Hospital Dubrava, Avenija Gojka Suska 6, Zagreb 10000, CroatiaDepartment of Gastroenterology, University of Zagreb School of Medicine, University Hospital Merkur, Zajceva ul. 19, Zagreb 10000, Croatia5th Department of Internal Medicine, Subdivision of Gastroenterology and Hepatology, Comenius University Faculty of Medicine, University Hospital Bratislava, Ruzinovska 6, 826 06 Bratislava, SlovakiaClinic of Gastroenterological Internal Medicine, Comenius University in Bratislava, University Hospital Martin, Kollarova 2, 036 59 Martin, SlovakiaDepartment of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, Zagreb 10000, CroatiaDepartment of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, Zagreb 10000, CroatiaDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kispaticeva ul. 12, Zagreb 10000, Croatia2nd Department of Internal Medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, SlovakiaDepartment of Mathematics and Theoretical Informatics, Technical University of Kosice, Bozeny Nemcovej 32, 040 01 Kosice, Slovakia2nd Department of Internal Medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, SlovakiaBackground. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim. To independently evaluate the predictive performance of the URS model. Methods. We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. Results. One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. Conclusion. Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.http://dx.doi.org/10.1155/2021/9928065 |
| spellingShingle | Jakub Gazda Martin Janicko Sylvia Drazilova Ivica Grgurevic Tajana Filipec Kanizaj Tomas Koller Beatrica Bodorovska Maja Mijic Ivana Mikolasevic Ivana Knezevic Stromar Branislav Kucinsky Matej Gazda Peter Jarcuska External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis Canadian Journal of Gastroenterology and Hepatology |
| title | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
| title_full | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
| title_fullStr | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
| title_full_unstemmed | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
| title_short | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
| title_sort | external validation of udca response score in slovak and croatian patients with primary biliary cholangitis |
| url | http://dx.doi.org/10.1155/2021/9928065 |
| work_keys_str_mv | AT jakubgazda externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT martinjanicko externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT sylviadrazilova externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT ivicagrgurevic externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT tajanafilipeckanizaj externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT tomaskoller externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT beatricabodorovska externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT majamijic externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT ivanamikolasevic externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT ivanaknezevicstromar externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT branislavkucinsky externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT matejgazda externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT peterjarcuska externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis |